In this real‐life multicenter study from Southern Italy, our results are consistent with previously reported studies, indicating a solid benefit for low genetic risk, especially for CBF AML, although not statistically significant likely because of the small number of patients with this genetic alteration in our cohort. The gene discussed is CEBPZ; the disease is acute myeloid leukemia.